Lund, Sweden – March 7, 2024 – Fåhraeus Startup & Growth Fund II (FSG) today announces its investment in Promimic, a Swedish nanotechnology company whose HAnano Surface enhances the integration of medical implants into bone. The investment establishes FSG as a strategic shareholder in Promimic, which is listed on Nasdaq First North Growth Market in Stockholm.

Promimic, a spin-out from Chalmers University of Technology, has developed HAnano Surface, a 20-nanometre bioactive coating that mimics natural bone to improve implant integration. Its technology has been used in more than 700,000 implant procedures worldwide, across dental, spine, joint, extremities and sports-medicine applications.

“Promimic’s HAnano Surface is a proven technology already used in hundreds of thousands of procedures. We believe the company has substantial room to grow as more implant manufacturers adopt bioactive surfaces, and we are glad to become a long-term shareholder,” said Emanuel Stihl, Partner at FSG.

“FSG’s investment strengthens our position as we expand globally. Their experience scaling life-science companies will be valuable as we deepen partnerships with leading implant manufacturers,” said Magnus Larsson, CEO of Promimic.

About Promimic

Promimic is a Swedish nanotechnology company and a spin-out from Chalmers University of Technology. Its HAnano Surface creates a unique bioactive surface on medical implants to facilitate their integration into bone, and has been used in more than 700,000 procedures worldwide. Promimic is listed on Nasdaq First North Growth Market in Stockholm.

About Fåhraeus Startup & Growth (FSG)

Fåhraeus Startup & Growth FSG Fund II (FSG) is a leading Nordic venture capital fund specializing in supporting high-impact startups and growth-stage companies in technology and life sciences. FSG combines strategic investments with deep industry expertise to empower transformative innovations. FSG Fund II is supported by the European Investment Fund (EIF).